ECOG-ACRIN Cancer Research Group

Clinical trial EA4231, led by Christopher Melani, MD of , is testing the effectiveness of a combination targeted therapy for patients with aggressive B-cell that has recurred or is resistant to treatment. For more: https://bit.ly/EA4231

Urothelial cancer is the most common type of bladder cancer. The EA8192 study is evaluating durvalumab and chemotherapy for patients with high grade upper tract urothelial cancer prior to nephroureterectomy. https://bit.ly/ea8192-trialhttps://bit.ly/ea8192-trial

Do you have that was recently removed by surgery? If so, you may be eligible for clinical trial EA1242/RxFINE-Low, a study exploring potential new treatment approaches. More info: https://bit.ly/ea1242-study

What makes cancer research better? Patient voices. 🗣️This National Cancer Survivors Month, we're recognizing ’s Cancer Research Advocates—survivors and caregivers who help shape clinical trials and advance patient-centered research.

The EA5221/ACHIEVE clinical study is testing two different treatment approaches for older adults with advanced non-small cell . Learn more: https://bit.ly/ea5221-achieve

EA7211/STRASS 2, led in the US by Dr. Kenneth Cardona, is the second randomized study ever performed in retroperitoneal soft tissue & is enrolling patients in the US, Europe, Canada, Australia, New Zealand, & Japan! Learn more: https://bit.ly/EA7211

EA1241, led by Dr. Joseph Sparano of , is a companion study for patients who previously took part in either the TAILORx (PACCT-1) or RxPONDER (S1007) breast cancer trials. Learn more: https://bit.ly/EA1241

Patients with newly diagnosed multiple myeloma may be eligible to participate in clinical trial EAA181/EQUATE. Learn more here: https://bit.ly/eaa181equate

Michael Lidsky, MD of is leading EA2222/PUMP, a randomized phase 3 study for patients with colorectal liver metastases. Learn more: https://bit.ly/ea2222-pump

Monika Joshi, MD and Petros Grivas, MD, PhD are leading clinical trial EA8231, a phase 3 randomized trial comparing the effectiveness of pembrolizumab and sacituzumab govitecan to standard-of-care chemotherapy in patients with advanced urothelial cancer. https://bit.ly/ea8231-study